Waveline-007: Dose escalation and confirmation, and efficacy expansion trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in patients with diffuse large B cell lymphoma

ROR1-targeting antibody-drug conjugate zilovertamab vedotin plus R-CHP demonstrated highly promising efficacy among patients with previously untreated DLBCL, according to results of the phase 2 WAVELINE-007 trial presented during the 2024 American Society of Hematology Annual Meeting. This dose-escalation trial established the recommended phase 2 dose (RP2D) of 1.75 mg/kg every 3 weeks, and patients receiving the RP2D (n=15) achieved a 100% objective response rate (95% CI: 78.2%-100.0%). Patients across all dose groups (n=36) achieved a 97.2% ORR (95% CI: 85.5%-99.9%).